MILLENNIUM PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
A Study of IXAZOMIB in Adult Patients With Lymphoma
- First Posted Date
- 2009-05-06
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT00893464
- Locations
- 🇺🇸
Tower Cancer Research Center, Beverly Hills, California, United States
🇺🇸University of Wisconsin Madison, Madison, Wisconsin, United States
🇨🇦Jewish General Hospital, Montreal, Quebec, Canada
MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT00853307
- Locations
- 🇺🇸
Summit Medical Group, Berkeley Heights, New Jersey, United States
Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab
- Conditions
- Follicular Lymphoma
- Interventions
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2012-12-12
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00850499
- Locations
- 🇬🇷
Laiko Hospital - 1st Dept. of Propaedeutic Internal Medicine, Athens, Greece
🇮🇱Sheba MC - Hematology Institute, Ramat Gan, Israel
🇮🇱Hadassah University Hospital - Hematology Department, Jerusalem, Israel
Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies
- Conditions
- Advanced Solid Tumors
- Interventions
- Biological: TAK-701
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2011-12-02
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT00831896
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸The Sarah Cannon Research Institute, Nashville, Tennessee, United States
A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies
- First Posted Date
- 2009-01-28
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT00830869
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸University of Washington- Seattle Cancer Care, Seattle, Washington, United States
A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
- Conditions
- High-Grade Myelodysplastic SyndromeAcute Myelogenous Leukemia
- Interventions
- First Posted Date
- 2009-01-28
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT00830518
- Locations
- 🇺🇸
Hematology and Oncology Associates of Northern New Jersey, Morristown, New Jersey, United States
Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma
- Conditions
- Burkitt's LymphomaTransformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell ComponentDiffuse Large B-cell LymphomaT-cell Lymphoma, Excluding Primary Cutaneous T-cell LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2008-12-12
- Last Posted Date
- 2018-03-27
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT00807495
- Locations
- 🇺🇸
Hematology Oncology Associates, Virtua Memorial Hospital Burlington County, Mount Holly, New Jersey, United States
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
- Conditions
- Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaChronic Myelogenous LeukemiaChronic Lymphocytic LeukemiaMultiple MyelomaWaldenstrom's MacroglobulinemiaMyelodysplastic SyndromePhiladelphia Chromosome-negative CMLMyeloid MetaplasiaMyelofibrosis
- Interventions
- First Posted Date
- 2008-12-12
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT00807677
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis
- First Posted Date
- 2008-11-02
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 895
- Registration Number
- NCT00783718
- Locations
- 🇺🇸
Gastroenterology Associates of Central Georgia, Macon, Georgia, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
- First Posted Date
- 2008-11-02
- Last Posted Date
- 2014-07-21
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 1116
- Registration Number
- NCT00783692
- Locations
- 🇺🇸
Puget Sound Medical Research, Edmonds, Washington, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Pittsburgh Medical Center - Cancer Centers, Pittsburgh, Pennsylvania, United States